Hackworth William A, Heuman Douglas M, Sanyal Arun J, Fisher Robert A, Sterling Richard K, Luketic Velimir A, Shiffman Mitchell L, Maluf Daniel G, Cotterell Adrian H, Posner Marc P, Stravitz Richard T
Liver Transplant Program, Hume-Lee Transplant Center, Virginia Commonwealth University Medical Center, Richmond, VA, USA.
Liver Int. 2009 Aug;29(7):1071-7. doi: 10.1111/j.1478-3231.2009.01982.x. Epub 2009 Mar 3.
Hyponatraemia increases risk of adverse outcomes following orthotopic liver transplantation (OLT), but it is unclear whether improvement of pretransplant hyponatraemia ameliorates post-transplant complications.
To assess impact of pretransplant hyponatraemia on post-transplant outcomes.
We performed a retrospective analysis of 213 patients with cirrhosis who underwent liver transplantation. Patients with serum sodium <or=130 mEq/L immediately before transplantation ('hyponatraemia at OLT'; n=34) were compared with those who had experienced hyponatraemia but subsequently improved to a serum sodium >130 mEq/L at transplantation ('resolved hyponatraemia'; n=56) and to those without history of hyponatraemia before transplantation ('never hyponatraemic'; n=123). Primary endpoint was survival at 180 days post-OLT. Secondary outcomes included time until discharge alive, complications during hospitalization, length of time ventilated and length of post-transplant intensive care unit stay.
There was no survival difference at 180 days post-OLT between groups. After transplantation, patients with either hyponatraemia at OLT or resolved hyponatraemia had longer time until discharge alive and had higher rates of delirium, acute renal failure, acute cellular rejection and infection than those who were never hyponatraemic. As compared with patients with hyponatraemia at OLT, those with resolved hyponatraemia were more likely to be discharged alive within 3 weeks, but other outcomes, including survival, did not differ significantly.
We conclude that hyponatraemia at any time before liver transplantation is associated with adverse post-transplant outcome, even when hyponatraemia has resolved.
低钠血症会增加原位肝移植(OLT)后不良结局的风险,但移植前低钠血症的改善是否能减轻移植后并发症尚不清楚。
评估移植前低钠血症对移植后结局的影响。
我们对213例接受肝移植的肝硬化患者进行了回顾性分析。将移植前即刻血清钠≤130 mEq/L的患者(“OLT时低钠血症”;n = 34)与曾有低钠血症但移植时血清钠随后升至>130 mEq/L的患者(“低钠血症已缓解”;n = 56)以及移植前无低钠血症病史的患者(“从未发生过低钠血症”;n = 123)进行比较。主要终点是OLT后180天的生存率。次要结局包括存活出院时间、住院期间的并发症、机械通气时间和移植后重症监护病房住院时间。
各组在OLT后180天的生存率无差异。移植后,OLT时低钠血症或低钠血症已缓解的患者存活出院时间更长,谵妄、急性肾衰竭、急性细胞排斥反应和感染的发生率高于从未发生过低钠血症的患者。与OLT时低钠血症的患者相比,低钠血症已缓解的患者更有可能在3周内存活出院,但包括生存率在内的其他结局无显著差异。
我们得出结论,肝移植前任何时候的低钠血症都与移植后不良结局相关,即使低钠血症已缓解。